Evaluation of Experimental and Commercial Air-Activated, Adhesive Backed Heat Patches

March 15, 2017 updated by: Chattem, Inc.
To assess the safety and tolerability for the extended wear of an experimental air-activated self adhesive patch.

Study Overview

Study Type

Interventional

Enrollment (Actual)

157

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Pinellas Park, Florida, United States, 33781
        • Radiant Research, Inc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participants are 18 to 70 years of age;
  • must be in general good health;
  • must have absence of any visible disease that might be confused with a skin reaction to the test material;
  • back region must be free from excessive hair, cuts, tatoos, or other aberrations;
  • must understand and sign Informed Consent;
  • must be considered dependable and able to follow directions;
  • Participants assigned to the thermocouples must be willing to restrict their activity for the 8 hour patch wear time so that the thermocouples do not come loose;
  • Participants assigned to the thermocouples must be willing to wear a pouch containing the thermostat and thermocouple wiring for the entire 8 hour period and to return all study supplies to the site at visit 15. If the items are not returned subject may be invoiced for the value of the unit;
  • must be willing to not wear any topical products such as lotions, sunscreens, etc. in the test area while participating in the study;
  • must agree to use an adequate means of birth control which include: abstinence, partner vasectomy, Intrauterine Device, hormonal implant devices/injections, regular use of birth control pills, birth control patches or condoms with a spermicidal agent;
  • Participants are willing to come in each day with a CLEAN back;
  • Participants who are 55 years of age and older, agree to supply a t-shirt to wear at visit two that can be marked on with a marker, and to use that t-shirt or supply others at the morning visits (visits 4, 6, 8, 10, 12, 14).

Exclusion Criteria:

  • Participants with known skin sensitivity to adhesion products;
  • Participants with any skin abnormality likely to be aggravated by the study material such as dermatological disease or infection, rash, atrophic, fragile, or abnormally dry skin, cuts or abrasions at the treatment site;
  • Participants who are pregnant or nursing, oral interview only;
  • Participants with diabetes or poor circulation;
  • Participants unable to tolerate conditions of protocol;
  • Participants viewed by the investigator as not being suitable for the study;
  • Participants who have had active skin cancer including basal cell carcinoma, or other cancer within one year;
  • Participants who are currently participating in another clinical trial;
  • Participants who routinely use anti-inflammatory medications (within 5 days of study start (81mg aspirin is okay)) or immunosuppressive or antihistamine medications within 3 weeks prior to study start (steroid nose/eye drops are ok);
  • Participants who currently use allergy injections;
  • Participants with history of severe asthma;
  • Participants with active or uncontrolled immunologic disorders i.e. AIDS, HIV positive, systemic lupus erythematosus, rheumatoid arthritis;
  • Participants with uncontrolled thyroid disease;
  • Participants who have any clinically significant chronic illness which could place the subject at increased risk during participation or result in inappropriate dermal response during the study;
  • Participants who have used topical medications at the test sites within the past 14 days;
  • Participants who have lower midline abdominal pinnicula which may interfere with heat patch/wrap application and or evaluation;
  • Participants who have a pacemaker, defibrillator or other implantable medical device;
  • Participants who have allergies to latex, polyethylene, polypropylene, nickel, chromium or aluminum.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Marketed Thermal Adhesive Patch
Group of subjects wearing comparative predicate device for 8 hours daily for 7 days.
Other Names:
  • ThermaCare Heat Wraps
Experimental: Thermal Adhesive Patch
Group of subjects wearing the experimental patch for 8 hours daily for 7 days.
Placebo Comparator: Placebo Patch
Group of subjects wearing the placebo patch for 8 hours daily for 7 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Irritation Evaluation
Time Frame: 7 days - 8 hours each day
A trained skin grader will apply a predetermined scale to the observed skin reactions in the test areas under light supplied by a 100-watt incandescent blue bulb.
7 days - 8 hours each day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adhesion Evaluation
Time Frame: after 8 hours
Adhesion will be evaluated to a predetermined scale when the subjects return for visits; after approximately 8 hours of wear time.
after 8 hours

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Heat Intensity
Time Frame: 8 hours
Assessed using thermocouple sensors worn between the patch and subject's skin with readings taken every 15 minutes.
8 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Daniel J Hogan, MD, Radiant Research

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2012

Primary Completion (Actual)

December 1, 2012

Study Completion (Actual)

December 1, 2012

Study Registration Dates

First Submitted

April 23, 2013

First Submitted That Met QC Criteria

April 24, 2013

First Posted (Estimate)

April 29, 2013

Study Record Updates

Last Update Posted (Actual)

March 17, 2017

Last Update Submitted That Met QC Criteria

March 15, 2017

Last Verified

April 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • 2012007

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tolerability

Clinical Trials on Placebo Patch

3
Subscribe